Literature DB >> 21115731

Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection.

Saifur Rahman1, Zafar K Khan, Brian Wigdahl, Stephen R Jennings, Frederic Tangy, Pooja Jain.   

Abstract

Human T cell leukemia virus type 1 (HTLV-1) is associated with two immunologically distinct diseases: HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T cell leukemia. We observed previously that depletion of dendritic cells (DCs) in CD11c-diphtheria toxin receptor transgenic mice followed by infection with cell-free virus led to greater proviral and Tax mRNA loads and diminished cellular immune response compared with mice infected with cell-associated virus. To understand the significance of these in vivo results and explore the host-pathogen interaction between DCs and cell-free HTLV-1, we used FLT3 ligand-cultured mouse bone marrow-derived DCs (FL-DCs) and chimeric HTLV-1. Phenotypically, the FL-DCs upregulated expression of surface markers (CD80, CD86, and MHC class II) on infection; however, the level of MHC class I remained unchanged. We performed kinetic studies to understand viral entry, proviral integration, and expression of the viral protein Tax. Multiplex cytokine profiling revealed production of an array of proinflammatory cytokines and type 1 IFN (IFN-α) by FL-DCs treated with virus. Virus-matured FL-DCs stimulated proliferation of autologous CD3(+) T cells as shown by intracellular nuclear Ki67 staining and produced IFN-γ when cultured with infected FL-DCs. Gene expression studies using type 1 IFN-specific and DC-specific arrays revealed upregulation of IFN-stimulated genes, most cytokines, and transcription factors, but a distinct downregulation of many chemokines. Overall, these results highlight the critical early responses generated by FL-DCs on challenge with cell-free chimeric HTLV-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115731      PMCID: PMC3224812          DOI: 10.4049/jimmunol.1002570

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion.

Authors:  M Osame; R Janssen; H Kubota; H Nishitani; A Igata; S Nagataki; M Mori; I Goto; H Shimabukuro; R Khabbaz
Journal:  Ann Neurol       Date:  1990-07       Impact factor: 10.422

2.  Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I.

Authors:  E L Murphy; B Hanchard; J P Figueroa; W N Gibbs; W S Lofters; M Campbell; J J Goedert; W A Blattner
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

3.  Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells.

Authors:  T Ohashi; S Hanabuchi; H Kato; Y Koya; F Takemura; K Hirokawa; T Yoshiki; Y Tanaka; M Fujii; M Kannagi
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad.

Authors:  E M Maloney; F R Cleghorn; O S Morgan; P Rodgers-Johnson; B Cranston; N Jack; W A Blattner; C Bartholomew; A Manns
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-02-01

5.  The role of human T-lymphotropic virus type 1 (HTLV-1)-infected dendritic cells in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  M Makino; S Shimokubo; S I Wakamatsu; S Izumo; M Baba
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

7.  Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis.

Authors:  A Ali; S Patterson; K Cruickshank; P Rudge; A G Dalgleish; S C Knight
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation.

Authors:  S E Macatonia; J K Cruickshank; P Rudge; S C Knight
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

9.  Human immature thymocytes as target cells of the leukemogenic activity of human T-cell leukemia virus type I.

Authors:  V Maguer-Satta; L Gazzolo; M D Dodon
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch.

Authors:  B L Kelsall; W Strober
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  13 in total

Review 1.  The tug-of-war between dendritic cells and human chronic viruses.

Authors:  Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

2.  In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine.

Authors:  Divya Sagar; Shet Masih; Todd Schell; Steven Jacobson; Joseph D Comber; Ramila Philip; Brian Wigdahl; Pooja Jain; Zafar K Khan
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

3.  An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1.

Authors:  Sharrón L Manuel; Mohit Sehgal; Zafar K Khan; James J Goedert; Michael R Betts; Pooja Jain
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-19       Impact factor: 2.205

Review 4.  HTLV-1 and innate immunity.

Authors:  Chloé Journo; Renaud Mahieux
Journal:  Viruses       Date:  2011-08-08       Impact factor: 5.048

5.  Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.

Authors:  Sonja Tattermusch; Jason A Skinner; Damien Chaussabel; Jacques Banchereau; Matthew P Berry; Finlay W McNab; Anne O'Garra; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2012-01-26       Impact factor: 6.823

Review 6.  Animal Models Utilized in HTLV-1 Research.

Authors:  Amanda R Panfil; Jacob J Al-Saleem; Patrick L Green
Journal:  Virology (Auckl)       Date:  2013-11-18

7.  Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives.

Authors:  Mineki Saito; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2012-02-06

Review 8.  Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Mineki Saito
Journal:  J Neurovirol       Date:  2013-08-14       Impact factor: 3.739

9.  Immunological profile of HTLV-1-infected patients associated with infectious or autoimmune dermatological disorders.

Authors:  Jordana Grazziela Alves Coelho-dos-Reis; Livia Passos; Mariana Costa Duarte; Marcelo Grossi Araújo; Ana Carolina Campi-Azevedo; Andréa Teixeira-Carvalho; Vanessa Peruhype-Magalhães; Bruno Caetano Trindade; Raquel Dos Santos Dias; Marina Lobato Martins; Anna Barbara de Freitas Carneiro-Proietti; Antônio Carlos Guedes; Denise Utsch Gonçalves; Olindo Assis Martins-Filho
Journal:  PLoS Negl Trop Dis       Date:  2013-07-25

10.  Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada.

Authors:  Benoit Barbeau; John Hiscott; Ali Bazarbachi; Edgar Carvalho; Kathryn Jones; Fabiola Martin; Masao Matsuoka; Edward L Murphy; Lee Ratner; William M Switzer; Toshiki Watanabe
Journal:  Retrovirology       Date:  2014-02-24       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.